ALLMedicine™ Immunofixation Center

May 7th, 2022 - Mass spectrometry (MS) techniques provide a highly sensitive methodology for the assessment and monitoring of paraproteins compared to standard electrophoretic techniques. The International Myeloma Working Group (IMWG) recently approved the use of...

Apr 3rd, 2022 - A woman in her 70s with vague gastrointestinal (GI) symptoms and unintentional weight loss was referred to endoscopy clinic for investigation and consideration of GI malignancy. CT of the thorax, abdomen and pelvis showed a suspicious mass in the ...

Mar 29th, 2022 - Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS) are based on predominantly White study populations screened by serum protein electrophoresis supplemented with immunofixation electrophoresis. A prevalence of 3% is...

Mar 7th, 2022 - The Diagnosis: Bullous Pyoderma Gangrenosum A bone marrow biopsy revealed 60% myeloblasts, leading to a diagnosis of acute myeloid leukemia (AML). A biopsy obtained from the edge of the bullous plaque demonstrated a dense dermal neutrophilic infil.

Mar 2nd, 2022 - Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant stage that almost always precedes multiple myeloma (MM) and amyloidosis. It is defined by a monoclonal-(M)-protein detected on serum protein electrophoresis ...

Dec 5th, 2018 - The term monoclonal gammopathy of renal significance (MGRS) was introduced by the International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012. The IKMG met in April 2017 to refine the definition of MGRS and to update the diagnosti...

Oct 21st, 2016 - Bing Neel syndrome is a rare disease manifestation of Waldenström's macroglobulinemia that results from infiltration of the central nervous system by malignant lymphoplasmacytic cells. In this guideline we describe the clinical symptoms, as well a...

Feb 5th, 2011 - A panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monocl...

Mar 2nd, 2022 - Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant stage that almost always precedes multiple myeloma (MM) and amyloidosis. It is defined by a monoclonal-(M)-protein detected on serum protein electrophoresis ...

Jan 26th, 2022 - To evaluate the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in Multiple Myeloma patients. 300 evaluable patients are required. For each of them, both spo...

Aug 16th, 2021 - Myeloma patients in first relapse after sibling or unrelated donor allogeneic transplant willing to participate in this study will be screened for eligibility. After baseline evaluation including BM aspirate for plasma cell count, minimal residual...

Jan 27th, 2021 - The investigators hypothesize that participants with earlier stages (NYHA Class I and Class II) of ATTR wild type and ATTR mutant will demonstrate stabilization of ATTR following 1 year of Tafamidis. The investigators propose to pursue the followi...

Nov 19th, 2019 - Background: Multiple myeloma (MM) is an incurable plasma cell neoplasm with a median survival of 3-4 years. Smoldering multiple myeloma (SMM) is a premalignant plasma cell disorder characterized by monoclonal protein greater than or equal to 3 g/d...

Mar 7th, 2022 - The Diagnosis: Bullous Pyoderma Gangrenosum A bone marrow biopsy revealed 60% myeloblasts, leading to a diagnosis of acute myeloid leukemia (AML). A biopsy obtained from the edge of the bullous plaque demonstrated a dense dermal neutrophilic infil.

Jun 15th, 2021 - Pyoderma gangrenosum (PG), a rare and painful ulcerative skin disorder, requires special care because “it’s a challenging diagnosis to make” and is frequently linked to serious comorbid conditions, a dermatologist told colleagues. PG is also chall.

Apr 26th, 2021 - Since the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.1 Nearly five y...

Apr 2nd, 2021 - Paul G. Richardson, MD: Saad, tell us about your own work with CANDOR, particularly the value of a PI [proteasome inhibitor] combined with a monoclonal antibody. It was pivotal work. Congratulations on the FDA approval very recently. That was terr...

Apr 2nd, 2021 - Paul G. Richardson, MD: Regarding MRD [minimal residual disease], Saad, if you could bring up the rear of this section and summarize where you see MRD assessment. As you’ve heard so nicely, MRD is giving us clues to what works best, and there was ...